Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
YMI024 · 1 trial · 1 indication
Change from baseline in log-transformed Interleukin-6 (IL-6) to evaluate the dose-response relationship using the Multiple Comparison Procedures (MCP) component of the Multiple Comparison Procedure-Modelling (MCP-Mod) methodology
| Arm | Type | Description |
|---|---|---|
| YMI024 Dose 1 | EXPERIMENTAL | Participants receive YMI024 Dose 1 in addition to standard-of-care therapies. |
| YMI024 Dose 2 | EXPERIMENTAL | Participants receive YMI024 Dose 2 in addition to standard-of-care therapies. |
| YMI024 Dose 3 | EXPERIMENTAL | Participants receive YMI024 Dose 3 in addition to standard-of-care therapies. |
| YMI024 Dose 4 | EXPERIMENTAL | Participants receive YMI024 Dose 4 in addition to standard-of-care therapies. |
| YMI024 Dose 5 | EXPERIMENTAL | Participants receive YMI024 Dose 5 in addition to standard-of-care therapies. |
| Placebo | PLACEBO_COMPARATOR | Participants receive a matching placebo in addition to standard-of-care therapies |
| Name | Type | Description |
|---|---|---|
| YMI024 | DRUG | YMI024 in different doses |
| Placebo | DRUG | matching placebo |
Inclusion Criteria: 1. Signed informed consent must be obtained prior to any study specific procedures, and participant able to understand and comply with study requirements. 2. Male and female participants aged between 18-80 years (inclusive) at Screening. 3. Documented stable CAD as evidenced by ...
Top 11 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Inclisiran, YMI024 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | Ziltivekimab |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| Viatris, Inc. | VTRS | 1 | PHASE3 | Selatogrel |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | obicetrapib+ ezetimibe daily |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE2 | Regadenoson |
| Humacyte, Inc. | HUMA | 1 | PHASE2 | CTEV |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 2 | - | alirocumab |
| Bayer | BAYRY | 1 | PHASE1 | Nurandociguat |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7763505 |
YMI024 is being studied for the treatment of coronary artery disease, specifically in adults with stable coronary artery disease and elevated hsCRP. It is an investigational small molecule developed by Novartis AG and is currently in Phase 2 clinical development.
YMI024 is being developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the Phase 2 clinical program evaluating the drug in patients with stable coronary artery disease and elevated hsCRP.
YMI024 is in Phase 2 clinical development. It has not been approved by the FDA and remains investigational. The ongoing Phase 2 trial is a dose-finding study designed to assess efficacy, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP.
YMI024 is being evaluated in one clinical trial, NCT07830719, titled a dose-finding study to assess efficacy, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP. The trial is currently recruiting and plans to enroll 180 participants across the United States, Australia, Germany, Japan, and the United Kingdom.
The YMI024 Phase 2 trial, NCT07830719, is a randomized, double-blind, placebo-controlled dose-finding study. It plans to enroll 180 adults aged 18 years and older with stable coronary artery disease and elevated hsCRP. Participants are being recruited across sites in the United States, Australia, Germany, Japan, and the United Kingdom.